<!DOCTYPE html >
<html lang="en">
<head>
<meta http-equiv="X-UA-Compatible" content="IE=Edge" />
<meta charset="utf-8" />
</head>

<body style="margin: 0;">

<div id="p144" style="overflow: hidden; position: relative; background-color: white; width: 433px; height: 649px;">

<!-- Begin shared CSS values -->
<style class="shared-css" type="text/css" >
.t {
	-webkit-transform-origin: top left;
	-moz-transform-origin: top left;
	-o-transform-origin: top left;
	-ms-transform-origin: top left;
	-webkit-transform: scale(0.25);
	-moz-transform: scale(0.25);
	-o-transform: scale(0.25);
	-ms-transform: scale(0.25);
	z-index: 2;
	position: absolute;
	white-space: pre;
	overflow: visible;
}
</style>
<!-- End shared CSS values -->


<!-- Begin inline CSS -->
<style type="text/css" >

#t1_144{left:4px;top:233px;letter-spacing:-0.1px;}
#t2_144{left:4px;top:78px;letter-spacing:-0.3px;}
#t3_144{left:5px;top:629px;}
#t4_144{left:52px;top:40px;letter-spacing:-1px;}
#t5_144{left:59px;top:40px;letter-spacing:-1px;}
#t6_144{left:95px;top:40px;letter-spacing:-1px;word-spacing:2.8px;}
#t7_144{left:201px;top:40px;letter-spacing:-0.9px;word-spacing:2.8px;}
#t8_144{left:59px;top:56px;letter-spacing:-1px;word-spacing:6.6px;}
#t9_144{left:59px;top:71px;letter-spacing:-1px;word-spacing:-0.1px;}
#ta_144{left:52px;top:88px;letter-spacing:-1px;}
#tb_144{left:59px;top:88px;letter-spacing:-1px;word-spacing:1.5px;}
#tc_144{left:149px;top:88px;letter-spacing:-1px;word-spacing:1.5px;}
#td_144{left:59px;top:104px;letter-spacing:-1px;word-spacing:-0.1px;}
#te_144{left:43px;top:138px;letter-spacing:-1px;word-spacing:-0.1px;}
#tf_144{left:52px;top:156px;letter-spacing:-1px;}
#tg_144{left:59px;top:156px;letter-spacing:-0.9px;word-spacing:3.3px;}
#th_144{left:59px;top:171px;letter-spacing:-1px;word-spacing:1px;}
#ti_144{left:59px;top:186px;letter-spacing:-1px;word-spacing:-1.8px;}
#tj_144{left:59px;top:202px;letter-spacing:-0.9px;word-spacing:0.4px;}
#tk_144{left:59px;top:217px;letter-spacing:-1px;word-spacing:0.1px;}
#tl_144{left:59px;top:232px;letter-spacing:-1px;word-spacing:-0.1px;}
#tm_144{left:52px;top:250px;letter-spacing:-1px;}
#tn_144{left:59px;top:250px;letter-spacing:-1px;word-spacing:2.2px;}
#to_144{left:59px;top:265px;letter-spacing:-1px;word-spacing:4px;}
#tp_144{left:59px;top:280px;letter-spacing:-1px;word-spacing:-1.9px;}
#tq_144{left:59px;top:296px;letter-spacing:-0.9px;word-spacing:-0.6px;}
#tr_144{left:59px;top:311px;letter-spacing:-1px;word-spacing:-1.1px;}
#ts_144{left:52px;top:328px;letter-spacing:-1px;word-spacing:-0.2px;}
#tt_144{left:69px;top:490px;}
#tu_144{left:75px;top:515px;}
#tv_144{left:212px;top:515px;}
#tw_144{left:230px;top:515px;}
#tx_144{left:69px;top:364px;}
#ty_144{left:102px;top:376px;}
#tz_144{left:205px;top:376px;}
#t10_144{left:58px;top:388px;}
#t11_144{left:262px;top:388px;}
#t12_144{left:282px;top:388px;}
#t13_144{left:151px;top:401px;}
#t14_144{left:44px;top:425px;word-spacing:1.6px;}
#t15_144{left:44px;top:435px;word-spacing:-1.3px;}
#t16_144{left:44px;top:446px;word-spacing:4.1px;}
#t17_144{left:44px;top:457px;}
#t18_144{left:43px;top:544px;word-spacing:0.5px;}
#t19_144{left:43px;top:555px;}

.s1_144{
	FONT-SIZE: 48.9px;
	FONT-FAMILY: AllerDisplay_lq;
	color: rgb(156,100,158);
}

.s2_144{
	FONT-SIZE: 48.9px;
	FONT-FAMILY: AllerDisplay_lq;
	color: rgb(35,31,32);
}

.s3_144{
	FONT-SIZE: 39.7px;
	FONT-FAMILY: AllerDisplay_lq;
	color: rgb(255,255,255);
}

.s4_144{
	FONT-SIZE: 48.9px;
	FONT-FAMILY: Helvetica-Condensed-Bold_j0;
	color: rgb(35,31,32);
}

.s5_144{
	FONT-SIZE: 48.9px;
	FONT-FAMILY: Helvetica-Condensed_ix;
	color: rgb(35,31,32);
}

.s6_144{
	FONT-SIZE: 36.7px;
	FONT-FAMILY: Helvetica-Condensed_ix;
	color: rgb(35,31,32);
}

.s7_144{
	FONT-SIZE: 30.6px;
	FONT-FAMILY: Helvetica-Condensed-Obliq_ka;
	color: rgb(35,31,32);
}

.t.m0_144{
	-webkit-transform: matrix(0,-1,1,0,0, 0) scale(0.25);
	-ms-transform: matrix(0,-1,1,0,0, 0) scale(0.25);
	-moz-transform: matrix(0,-1,1,0,0, 0) scale(0.25);
	-o-transform: matrix(0,-1,1,0,0, 0) scale(0.25);
}

</style>
<!-- End inline CSS -->

<!-- Begin embedded font definitions -->
<style id="fonts144" type="text/css" >

@font-face {
	font-family: Helvetica-Condensed-Obliq_ka;
	src: url("fonts/Helvetica-Condensed-Obliq_ka.woff") format("woff");
}

@font-face {
	font-family: Helvetica-Condensed-Bold_j0;
	src: url("fonts/Helvetica-Condensed-Bold_j0.woff") format("woff");
}

@font-face {
	font-family: AllerDisplay_lq;
	src: url("fonts/AllerDisplay_lq.woff") format("woff");
}

@font-face {
	font-family: Helvetica-Condensed_ix;
	src: url("fonts/Helvetica-Condensed_ix.woff") format("woff");
}

</style>
<!-- End embedded font definitions -->

<!-- Begin page background -->
<div id="pg144Overlay" style="width:100%; height:100%; position:absolute; z-index:1; background-color:rgba(0,0,0,0); -webkit-user-select: none;"></div>
<div id="pg144" style="-webkit-user-select: none;"><object width="433" height="649" data="144/144.svg" type="image/svg+xml" id="pdf144" style="width:433px; height:649px; -moz-transform:scale(1); z-index: 0;"></object></div>
<!-- End page background -->


<!-- Begin text definitions (Positioned/styled in CSS) -->
<div id="t1_144" class="t m0_144 s1_144">O Guia do Jovem Internista </div>
<div id="t2_144" class="t m0_144 s2_144">2016</div>
<div id="t3_144" class="t s3_144">142</div>
<div id="t4_144" class="t s4_144">- </div>
<div id="t5_144" class="t s4_144">Fonte: </div>
<div id="t6_144" class="t s5_144">serologias virais para </div>
<div id="t7_144" class="t s5_144">VHB (AgHBs), VHC (antiVHC) e VIH </div>
<div id="t8_144" class="t s5_144">(teste de 4ª geração, com pesquisa de do Ag p24); se positivos, </div>
<div id="t9_144" class="t s5_144">pedir carga viral</div>
<div id="ta_144" class="t s4_144">- </div>
<div id="tb_144" class="t s4_144">Indivíduo exposto:</div>
<div id="tc_144" class="t s5_144">Anti VIH, AgHBs, Ac anti-HBs, Ac anti-HBc, An-</div>
<div id="td_144" class="t s5_144">ti-VHC, hemograma e transaminases hepáticas. Teste de gravidez.</div>
<div id="te_144" class="t s4_144">• Infeção pelo vírus da imunodeficiência humana (VIH)</div>
<div id="tf_144" class="t s5_144">• </div>
<div id="tg_144" class="t s5_144">O risco estimado de infecção VIH após exposição percutânea é de </div>
<div id="th_144" class="t s5_144">0,3%. A exposição a uma fonte com carga viral não detectável, não </div>
<div id="ti_144" class="t s5_144">elimina a possibilidade de transmissão VIH ou a necessidade de PPE </div>
<div id="tj_144" class="t s5_144">ou de follow-up. Risco de infecção VIH se lesão percutânea (agulha </div>
<div id="tk_144" class="t s5_144">ou objecto cortante), contacto de pele não integra ou mucosas com </div>
<div id="tl_144" class="t s5_144">tecidos, sangue ou outros fluidos potencialmente infectantes.</div>
<div id="tm_144" class="t s5_144">• </div>
<div id="tn_144" class="t s5_144">Início da profilaxia deve ser IMEDIATO nas situações de risco (não </div>
<div id="to_144" class="t s5_144">atrasar início até ao resultado das serologias), idealmente nas pri-</div>
<div id="tp_144" class="t s5_144">meiras 2h após exposição podendo extender-se até às 72h, sabendo </div>
<div id="tq_144" class="t s5_144">que a eficácia será menor. Ainda assim, não existe bem definido um </div>
<div id="tr_144" class="t s5_144">tempo absoluto após o qual a profilaxia não possa ser administrada.</div>
<div id="ts_144" class="t s5_144">• Esquemas profiláticos preconizados (1ª linha):</div>
<div id="tt_144" class="t s6_144">Tenofovir (TDF) 300 mg + Emtricitabina (FTC) 200 mg/dia (Truvada®) 1xdia</div>
<div id="tu_144" class="t s6_144">+ Raltegravir (RAL) 400 mg 12/12h </div>
<div id="tv_144" class="t s6_144">ou </div>
<div id="tw_144" class="t s6_144">Dolutegravir (DTG) 50 mg/dia</div>
<div id="tx_144" class="t s6_144">Tenofovir (TDF) 300 mg + Emtricitabina (FTC) 200 mg/dia (Truvada®) 1xdia</div>
<div id="ty_144" class="t s6_144">ou Tenofovir (TDF) 300 mg </div>
<div id="tz_144" class="t s6_144">1xd +Lamivudina 300mg 1xd</div>
<div id="t10_144" class="t s6_144">+ Lopinavir/Ritonavir (LPV/r) 400 mg/100 mg 12/12h </div>
<div id="t11_144" class="t s6_144">ou </div>
<div id="t12_144" class="t s6_144">Atazanavir/ ritonavir </div>
<div id="t13_144" class="t s6_144">(ATV/r) 300 mg/100 mg 1x/dia</div>
<div id="t14_144" class="t s7_144">Guidelines on post-exposure prophylaxis for HIV and the use of co-trimoxazole prophylaxis for HIV-related </div>
<div id="t15_144" class="t s7_144">infections among adults, adolescents and children: recommendations for a public health approach: December </div>
<div id="t16_144" class="t s7_144">2014 supplement to the 2013 consolidated guidelines on the use of antiretroviral drugs for treating and </div>
<div id="t17_144" class="t s7_144">preventing HIV infection. OMS/WHO 2014)</div>
<div id="t18_144" class="t s7_144">HIV prophylaxis following occupational exposure guidelines, New York Department of Health AIDS Institute. </div>
<div id="t19_144" class="t s7_144">Oct 2014</div>

<!-- End text definitions -->


</div>
</body>
</html>
